The cannabinoid receptors are members of the guanine-nucleotide-binding protein (G-protein) coupled receptor family. They inhibit adenylate cyclase activity in a dose-dependent, stereoselective and pertussis toxin-sensitive manner. The two cannabinoid receptors play and important role in the cannabinoid-induced CNS effects, including alterations in mood and cognition. Changes in endocannabinoid levels and/or CB₂ receptor expressions have been reported in almost all diseases affecting humans; such as cardiovascular, gastrointestinal, liver, kidney, neurodegenerative, psychiatric, bone, skin, autoimmune, lung disorders or pain and cancer. The prevalence of this trend suggests that modulating CB₂ receptor activity by either selective CB₂ receptor agonists or inverse agonists/antagonists depending on the disease and its progression holds unique therapeutic potential for these pathologies. HiTSeeker CB₂ Cannabinoid Receptor Cell Line from Innoprot allows the measurement of the activity and potency of ligands; such as CP55940.